Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella Pneumoniae

Overview

Journal Ann Transplant

Specialty General Surgery

Date 2023 May 16

PMID 37190675

Authors

Piotr Wilkowski

Ewa Hryniewiecka

Kornelia Jasinska

Leszek Paczek

Michal Ciszek

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Carbapenems are the primary treatment for urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae. However, the recurrence rate is high, and patients often require rehospitalization. We present the results of an observational study on patients with recurrent UTIs who were treated in an outpatient setting with maximal therapeutic oral doses of amoxicillin with clavulanic acid. MATERIAL AND METHODS All patients had pyuria and ESBL-producing K. pneumoniae in urine culture. The starting dosage was 2875 g of amoxicillin twice daily and 125 mg of clavulanic acid twice daily. We down-titrated the doses every 7-14 days and continued prophylactic therapy with amoxicillin/clavulanic acid at 250/125 mg for up to 3 months. We defined therapeutic failure as ESBL-positive K. pneumoniae in urine culture during therapy and recurrence as positive urine culture with the same strain within 1 month after the end of treatment. RESULTS We included 9 patients: 7 kidney graft recipients, 1 liver graft recipient, and 1 patient with chronic kidney disease. We observed no therapeutic failures and no recurrences in the study group during the study period. In 1 case, the patient experienced a subsequent UTI caused by ESBL-producing K. pneumoniae 4 months after completing the therapy. CONCLUSIONS In conclusion, it is possible to break the resistance of ESBL-producing K. pneumoniae strains with high doses of oral amoxicillin with clavulanic acid. Such treatment could be an alternative to carbapenems in select cases.

References

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A . Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). PMC: 5967687. DOI: 10.1128/CMR.00079-17. View

Lopez-Medrano F, Tiago Silva J, Fernandez-Ruiz M, Vidal E, Origuen J, Calvo-Cano A . Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-Results of a Spanish multicenter cohort. Am J Transplant. 2019; 20(2):451-462. DOI: 10.1111/ajt.15614. View

Lee C, Lee J, Park K, Jeon J, Kim Y, Cha C . Antimicrobial Resistance of Hypervirulent : Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms. Front Cell Infect Microbiol. 2017; 7:483. PMC: 5702448. DOI: 10.3389/fcimb.2017.00483. View

Gorrie C, Mirceta M, Wick R, Edwards D, Thomson N, Strugnell R . Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in Intensive Care Patients. Clin Infect Dis. 2017; 65(2):208-215. PMC: 5850561. DOI: 10.1093/cid/cix270. View

Chong Y, Shimoda S, Shimono N . Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol. 2018; 61:185-188. DOI: 10.1016/j.meegid.2018.04.005. View

Rajapakse N, Vayalumkal J, Vanderkooi O, Ricketson L, Kellner J . Time to reconsider routine high-dose amoxicillin for community-acquired pneumonia in all Canadian children. Paediatr Child Health. 2016; 21(2):65-6. PMC: 4807794. DOI: 10.1093/pch/21.2.65. View

Pierrotti L, Perez-Nadales E, Fernandez-Ruiz M, Gutierrez-Gutierrez B, Tan B, Carratala J . Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). Transpl Infect Dis. 2020; 23(3):e13520. DOI: 10.1111/tid.13520. View

Dean B, Lopez G, Krenzelok E . The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30(1):66-7. View

Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J . Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013; 96(9):843-9. DOI: 10.1097/TP.0b013e3182a049fd. View

10.

Gutierrez-Gutierrez B, Rodriguez-Bano J . Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect. 2019; 25(8):932-942. DOI: 10.1016/j.cmi.2019.03.030. View

11.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017; 18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3. View

12.

Pilmis B, Scemla A, Join-Lambert O, Mamzer M, Lortholary O, Legendre C . ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence. Infect Dis (Lond). 2015; 47(10):714-8. DOI: 10.3109/23744235.2015.1051107. View

13.

Harris P, Tambyah P, Paterson D . β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis. 2015; 15(4):475-85. DOI: 10.1016/S1473-3099(14)70950-8. View

14.

deLemos A, Ghabril M, Rockey D, Gu J, Barnhart H, Fontana R . Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci. 2016; 61(8):2406-2416. PMC: 4945382. DOI: 10.1007/s10620-016-4121-6. View

15.

Padmini N, Ajilda A, Sivakumar N, Selvakumar G . Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. J Basic Microbiol. 2017; 57(6):460-470. DOI: 10.1002/jobm.201700008. View

16.

Alevizakos M, Nasioudis D, Mylonakis E . Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2017; 19(6). DOI: 10.1111/tid.12759. View

17.

Pouch S, Kubin C, Satlin M, Tsapepas D, Lee J, Dube G . Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl Infect Dis. 2015; 17(6):800-9. PMC: 4715525. DOI: 10.1111/tid.12450. View

18.

Prokesch B, TeKippe M, Kim J, Raj P, Tekippe E, Greenberg D . Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae. Lancet Infect Dis. 2016; 16(9):e190-e195. DOI: 10.1016/S1473-3099(16)30021-4. View

19.

Fiorentino M, Pesce F, Schena A, Simone S, Castellano G, Gesualdo L . Updates on urinary tract infections in kidney transplantation. J Nephrol. 2019; 32(5):751-761. DOI: 10.1007/s40620-019-00585-3. View

20.

Zullo A, Ridola L, De Francesco V, Gatta L, Hassan C, Alvaro D . High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015; 28(4):448-51. PMC: 4585390. View